An Official Website of the United States Government
Studies in Mice to Improve Efficacy/Safety of Paclitaxel/Docetaxel with an…
- Small Business Information
-
Woman-Owned: NoMinority-Owned: NoHUBZone-Owned: No
- Phase 1
-
Fiscal Year: 2010Title: Studies in Mice to Improve Efficacy/Safety of Paclitaxel/Docetaxel with an Anti-IAgency: HHSContract: 1R43CA150448-01Award Amount: $163,150.00
Abstract:
DESCRIPTION (provided by applicant): Inhibitor of differentiation (Id) genes and proteins play a significant role in tumor biology, and an anti-Id therapy in combination with a taxanes, a widely prescribed class of cytotoxic (paclitaxel/docetaxel, docetaxe l or protein-bound paclitaxel) to treat cancer, is hypothesized to significantly improve the efficacy of the taxane without compromising safety while also providing additional anti-cancer activity. An effective Id1 inhibitor would potentially improve the e fficacy of the taxanes by three distinct mechanisms: (i) preventing endothelial repair and thereby promoting the intrinsic anti-angiogenic effect of paclitaxel/docetaxel, (ii) lowering the anti-apoptotic environment of the tumor making it more susceptible to the cytotoxicity of paclitaxel/docetaxel and (iii) augmenting the cytotoxicity of paclitaxel/docetaxel by a direct anti-cancer effect. The goal of this proposal is to provide data to justify formal preclinical development and initial clinical evaluation of this therapeutic approach with an anti-Id1 small molecule. Experiments to be funded by the grant include xenograft studies in mice to establish the optimum dosing regimen for both the anti-Id agent and the taxanes. PUBLIC HEALTH RELEVANCE: Anti- microtubule taxanes like paclitaxel and docetaxel are widely prescribed cytotoxics to treat cancer. An effective Id1 inhibitor would potentially improve the efficacy of taxanes by three distinct mechanisms: (i) preventing endothelial repair and thereby pro moting the intrinsic anti-angiogenic effect of taxanes, (ii) lowering the anti-apoptotic environment of the tumor making it more susceptible to the cytotoxicity of the taxanes, and (iii) augmenting the cytotoxicity of the taxanes by a direct anti-cancer ef fect. The goal of this proposal is to provide data to justify formal preclinical development and initial clinical evaluation of this therapeutic approach using an anti-Id1 small molecule.Small Business Information at Submission:ANGIOGENEX
ANGIOGENEX 425 MADISON AVE NEW YORK, NY 10017EIN/Tax ID: 113412407DUNS: N/ANumber of Employees: N/AWoman-Owned: NoMinority-Owned: NoHUBZone-Owned: No
Award Information
|
Agency: Department of Health and Human Services |
Branch: N/A |
Award ID: 95911 |
Program Year/Program: 2010 / SBIR |
|
Agency Tracking Number: CA150448 |
Solicitation Year: N/A |
Solicitation Topic Code: NCI |
Solicitation Number: N/A |